Drug Profile
Research programme: cancer and infectious diseases vaccines - ISA Pharmaceuticals
Alternative Names: Hepatitis B vaccine - ISA Pharmaceuticals; HPV SLP®-AMPLIVANT™ vaccine; HPV16-peptides-AMPLIVANT-vaccine; ISA 203; ISA-204; MyISA®; Peptide vaccines - ISA Pharmaceuticals; PRAME vaccine; SLP-AMPLIVANT-conjugate-head-and-neck-cancer-vaccine; SLP® vaccines; SLP®-AMPLIVANT™ conjugate vaccines; SLP®-AMPLIVANT™ melanoma vaccineLatest Information Update: 31 May 2023
Price :
$50
*
At a glance
- Originator ISA Pharmaceuticals
- Class Cancer vaccines; Conjugate vaccines; Hepatitis B vaccines; Immunotherapies; Peptide vaccines; Tuberculosis vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
- No development reported Hepatitis B; Tuberculosis; Viral infections
Most Recent Events
- 31 May 2023 Research programme is still in preclinical phase for Cancer in Netherlands (ISA Pharmaceuticals pipeline; May 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Hepatitis-B in Netherlands
- 28 Feb 2019 No recent reports of development identified for preclinical development in Cancer in Netherlands (Parenteral)